Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMAVAX-EGF + KRAS G12C Inhibitors in Advanced KRAS G12C Mutated NSCLC
NCT07543172Phase 2Not yet recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of cimavax egf in non-small cell lung cancer (NSCLC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cimavax egf
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07543172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543172.